Concentration of antifungal agents within host cell membranes: A new paradigm governing the efficacy of prophylaxis

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 12, 2011, Pages 5732-5739

  Campoli, P ^a   Al Abdallah, Q ^a   Robitaille, R ^b   Solis, N V ^c   Fielhaber, J A ^d   Kristof, A S ^d   Laverdiere, M ^b   Filler, S G ^c,e   Sheppard, D C ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MAISONNEUVE ROSEMONT HOSPITAL   (Canada)

^c UCLA MEDICAL CENTER   (United States)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; CASPOFUNGIN; ITRACONAZOLE; POSACONAZOLE; VORICONAZOLE;

ANIMAL CELL; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; DRUG EFFICACY; EPITHELIUM CELL; FUNGUS GROWTH; HOST CELL; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RAT;

ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; CELL LINE; CELL MEMBRANE; CHEMOPREVENTION; EPITHELIAL CELLS; HUMANS; ITRACONAZOLE; LUNG; MACROPHAGES; MYCOSES; TRIAZOLES;

EID: 81555206672     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00637-11     Document Type: Article

References (32)

1. Ballesta, S., I. Garcia, E. J. Perea, and A. Pascual. 2005. Uptake and intracellular activity of voriconazole in human polymorphonuclear leucocytes. J. Antimicrob. Chemother. 55:785-787. (Pubitemid 40691863)
2. Balloy, V., and M. Chignard. 2009. The innate immune response to Aspergillus fumigatus. Microbes Infect. 11:919-927.
3. Billaud, E. M., et al. 2010. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients. Med. Mycol. 48(Suppl. 1):S52-S59.
4. Conte, J. E., Jr., J. A. Golden, J. Kipps, M. McIver, and E. Zurlinden. 2004. Intrapulmonary pharmacokinetics and pharmacodynamics of itraconazole and 14-hydroxyitraconazole at steady state. Antimicrob. Agents Chemother. 48:3823-3827.
5. Conte, J. E., Jr., et al. 2009. Intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole at steady state in healthy subjects. Antimicrob. Agents Chemother. 53:703-707.
6. Cornely, O. A., et al. 2007. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359. (Pubitemid 46148777)
7. Cornely, O. A., and A. J. Ullmann. 2011. Lack of evidence for exposureresponse relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin. Pharmacol. Ther. 89:351-352.
8. Farowski, F., et al. 2010. Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry. Antimicrob. Agents Chemother. 54:1815-1819.
9. Fielhaber, J. A., et al. 2009. Inactivation of mammalian target of rapamycin increases STAT1 nuclear content and transcriptional activity in alpha4- and protein phosphatase 2A-dependent fashion. J. Biol. Chem. 284:24341-24353.
10. Gage, R., and D. A. Stopher. 1998. A rapid HPLC assay for voriconazole in human plasma. J. Pharm. Biomed. Anal. 17:1449-1453. (Pubitemid 29027752)
11. Groll, A. H., et al. 2010. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin B, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob. Agents Chemother. 54:4143-4149.
12. Groll, A. H., and A. Tragiannidis. 2009. Recent advances in antifungal prevention and treatment. Semin. Hematol. 46:212-229.
13. Hand, W. L., and D. L. Hand. 2001. Characteristics and mechanisms of azithromycin accumulation and efflux in human polymorphonuclear leukocytes. Int. J. Antimicrob. Agents 18:419-425. (Pubitemid 33065652)
14. Hoff, B., and U. Kuck. 2005. Use of bimolecular fluorescence complementation to demonstrate transcription factor interaction in nuclei of living cells from the filamentous fungus Acremonium chrysogenum. Curr. Genet. 47: 132-138. (Pubitemid 40227503)
15. Howard, S. J., et al. 2011. Pharmacokinetics and pharmacodynamics of posaconazole for invasive pulmonary aspergillosis: clinical implications for antifungal therapy. J. Infect. Dis. 203:1324-1332.
16. Hussaini, T., M. J. Ruping, F. Farowski, J. J. Vehreschild, and O. A. Cornely. 2001.Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy 31:214-225.
17. Jang, S. H., P. M. Colangelo, and J. V. Gobburu. 2010. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin. Pharmacol. Ther. 88:115-119.
18. Kim, J. E., and J. Chen. 2000. Cytoplasmic-nuclear shuttling of FKBP12- rapamycin-associated protein is involved in rapamycin-sensitive signaling and translation initiation. Proc. Natl. Acad. Sci. U. S. A. 97:14340-14345. (Pubitemid 32016577)
19. Lopes Bezerra, L. M., and S. G. Filler. 2004. Interactions of Aspergillus fumigatus with endothelial cells: internalization, injury, and stimulation of tissue factor activity. Blood 103:2143-2149. (Pubitemid 38326231)
20. Mavridou, E., R. J. Bruggemann, W. J. Melchers, J. W. Mouton, and P. E. Verweij. 2010. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob. Agents Chemother. 54:860-865.
21. NCCLS. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard. NCCLS document M38-A (ISBN 1-56238-470-8). NCCLS, Wayne, PA.
22. Pagano, L., M. Caira, C. G. Valentini, B. Posteraro, and L. Fianchi. 2010. Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Rev. 24:51-61.
23. Pascual, A., et al. 2008. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin. Infect. Dis. 46:201-211. (Pubitemid 351269158)
24. Pascual, A., et al. 2007. Variability of voriconazole plasma levels measured by new high-performance liquid chromatography and bioassay methods. Antimicrob. Agents Chemother. 51:137-143. (Pubitemid 46047698)
25. Smith, J., et al. 2006. Voriconazole therapeutic drug monitoring. Antimicrob. Agents Chemother. 50:1570-1572.
26. Spellig, T., A. Bottin, and R. Kahmann. 1996. Green fluorescent protein (GFP) as a new vital marker in the phytopathogenic fungus Ustilago maydis. Mol. Gen. Genet. 252:503-509.
27. Twumasi-Boateng, K., et al. 2009. Transcriptional profiling identifies a role for BrlA in the response to nitrogen depletion and for StuA in the regulation of secondary metabolite clusters in Aspergillus fumigatus. Eukaryot. Cell 8:104-115.
28. Ullmann, A. J., et al. 2007. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N. Engl. J. Med. 356:335-347. (Pubitemid 46148776)
29. Wasylnka, J. A., and M. M. Moore. 2002. Uptake of Aspergillus fumigatus conidia by phagocytic and nonphagocytic cells in vitro: quantitation using strains expressing green fluorescent protein. Infect. Immun. 70:3156-3163. (Pubitemid 34564179)
30. Wilson, D. T., R. H. Drew, and J. R. Perfect. 2009. Antifungal therapy for invasive fungal diseases in allogeneic stem cell transplant recipients: an update. Mycopathologia 168:313-327.
31. Wingard, J. R., et al. 2010. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116:5111-5118.
32. Wurch, T., F. Lestienne, and P. J. Pauwels. 1998. A modified overlap extension PCR method to create chimeric genes in the absence of restriction enzymes. Biotechnol. Tech. 12:653-657. (Pubitemid 28456279)